Diseases /
Primary Peritoneal Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary. Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively. The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement. [1]
Primary peritoneal carcinomas most frequently harbor alterations in TP53, KRAS, EPHB1, BRCA2, and BCOR [2].
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53fs, and TP53 Exon 8 Mutation are the most common alterations in primary peritoneal carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for primary peritoneal carcinoma, 4 are FDA-approved in at least one setting and 3 have NCCN guidelines in at least one setting [3].
Niraparib +
Disease is predicted to be sensitive: -
Olaparib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Maintenance therapy (FDA, NCCN) |
| Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy. |
Rucaparib +
Disease is predicted to be sensitive: -
Bevacizumab + Olaparib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Maintenance therapy (FDA) |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Clinical Trials
There are 191 clinical trials for primary peritoneal carcinoma, of which 149 are open and 42 are completed or closed. Of the trials that contain primary peritoneal carcinoma as an inclusion criterion, 4 are early phase 1 (4 open), 73 are phase 1 (49 open), 37 are phase 1/phase 2 (31 open), 57 are phase 2 (46 open), 2 are phase 2/phase 3 (2 open), 16 are phase 3 (15 open), and 2 are phase 4 (2 open).
BRCA1, BRCA2, and BARD1 are the most frequent gene inclusion criteria for primary peritoneal carcinoma clinical trials [3].
Paclitaxel, carboplatin, and olaparib are the most common interventions in primary peritoneal carcinoma clinical trials.
Significant Genes in Primary Peritoneal Carcinoma
ARID1A +
ARID1A is altered in 4.55% of primary peritoneal carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 4 clinical trials for primary peritoneal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ARID1A status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
ATM +
ATM is altered in 4.35% of primary peritoneal carcinoma patients [2].
ATM is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain ATM status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
ATR +
ATR is altered in 9.09% of primary peritoneal carcinoma patients [2].
ATR is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain ATR status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ATRX status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain BARD1 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
BRCA1 +
BRCA1 is altered in 4.55% of primary peritoneal carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 31 clinical trials for primary peritoneal carcinoma, of which 24 are open and 7 are closed. Of the trials that contain BRCA1 status and primary peritoneal carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), 5 are phase 3 (4 open), and 2 are phase 4 (2 open) [3].
Bevacizumab, olaparib, niraparib, and rucaparib have evidence of efficacy in patients with BRCA1 mutation in primary peritoneal carcinoma [3].
BRCA2 +
BRCA2 is altered in 13.64% of primary peritoneal carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 31 clinical trials for primary peritoneal carcinoma, of which 24 are open and 7 are closed. Of the trials that contain BRCA2 status and primary peritoneal carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), 5 are phase 3 (4 open), and 2 are phase 4 (2 open) [3].
Bevacizumab, olaparib, niraparib, and rucaparib have evidence of efficacy in patients with BRCA2 mutation in primary peritoneal carcinoma [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain BRIP1 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain C11orf30 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 9.09% of primary peritoneal carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain CDK12 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CDK4 +
CDK4 is altered in 4.55% of primary peritoneal carcinoma patients [2].
CDK4 is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain CHEK1 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain CHEK2 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
EGFR +
EGFR is altered in 4.35% of primary peritoneal carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 8.7% of primary peritoneal carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERCC2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERCC3 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC4 +
ERCC4 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERCC4 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC5 +
ERCC5 is altered in 6.25% of primary peritoneal carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERCC5 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
ERCC6 +
ERCC6 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERCC6 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain FANCA status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCB status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCC status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCD2 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCE status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCF status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCG status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCI status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain FANCL status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCM status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HDAC1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HDAC2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 6 clinical trials for primary peritoneal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain MCPH1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MDM2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MDM4 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MLF1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MLH1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MLH3 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain MRE11A status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH3 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MSH6 +
MSH6 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
MUTYH +
MUTYH is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MUTYH status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
NBN +
NBN is altered in 5.26% of primary peritoneal carcinoma patients [2].
NBN is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain NBN status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NPM1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain PALB2 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PARP1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PARP2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PMS1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PMS2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
POLE +
POLE is altered in 4.55% of primary peritoneal carcinoma patients [2].
POLE is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain POLE status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PPP2R1A status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 4 clinical trials for primary peritoneal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PPP2R2A status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 4 (1 open) [3].
PTEN +
PTEN is altered in 8.7% of primary peritoneal carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 6 clinical trials for primary peritoneal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain RAD50 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
RAD51 +
RAD51 is altered in 4.55% of primary peritoneal carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD51 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain RAD51B status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain RAD51C status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain RAD51D status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD54L +
RAD54L is an inclusion eligibility criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD54L status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain SLX4 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain SMARCB1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
STAG2 +
STAG2 is altered in 4.55% of primary peritoneal carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain STAG2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
STK11 +
STK11 is altered in 4.35% of primary peritoneal carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain STK11 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
TP53 +
TP53 is altered in 78.26% of primary peritoneal carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain XRCC1 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
